Enter 2027 Ready for Capital
A 30-day Capital Readiness Sprint for life sciences founders preparing to raise in 2027
You have a company to run. We pressure-test the business before the market does, giving you a clear view of what is ready, what investors are likely to challenge, and what needs to happen before you begin the raise.
30 days. Three lenses. Three concrete outputs. Fixed fee.
2027 Starts Before January
The 45th Annual J.P. Morgan Healthcare Conference takes place January 11–14, 2027 in San Francisco, bringing together global healthcare leaders, emerging companies and the investment community.
For life sciences founders planning to access capital in 2027, JPM Week marks an important opening to the new year, whether you are attending the conference itself or participating in the broader investor and partnering activity around San Francisco.
But the months before January are already crowded.
You are closing out 2026. Delivering development milestones. Managing runway. Finalizing budgets and operating plans. Working with your Board. Building the company. Preparing for the year ahead.
And somewhere in the middle of all of that, you also need to determine whether the company is actually ready to go in front of investors.
Time is scarce. Investor attention is scarcer.
Do not spend Q1 discovering what should have been addressed before the raise began.
Capital Is Moving. It Is Also Becoming More Selective
The healthcare funding market is not closed. But capital is increasingly concentrating around companies able to make a compelling, well-supported investment case. Healthcare venture investment reached approximately $31 billion across 1,101 deals in the first half of 2026. In biopharma alone, approximately $4.1 billion was invested across 95 first financings. But the largest 14 biopharma first-financing rounds accounted for approximately 70% of all dollars invested.
The Founder implication is simple: Having good science is not enough. Having an exciting market is not enough. And having an investor deck is not the same as being ready for investors.
Institutional capital requires a coherent case connecting the underlying opportunity, the capital being requested, the milestones it will fund, the value those milestones can create, and the organization expected to deliver them.
The stronger that case is before you enter the market, the better positioned you are when investor scrutiny begins.
This Is What the Capital Readiness Sprint Is Built to Solve
ClarityNorth Partners' 2027 Capital Readiness Sprint is a focused, 30-day independent assessment for life sciences companies expecting to pursue institutional capital in the year ahead.
We review the company through three interconnected capital-readiness lenses and challenge the investment case from the perspective of what sophisticated investors are likely to examine.
At the end of the Sprint, you should have clear answers to four questions:
What is ready?
What is not?
Why does it matter?
What should we do next?
This is deliberately not an open-ended consulting engagement.
The scope is fixed. The fee is fixed. The timeline is 30 days.
What You Receive
3 Concrete Outputs
01 | CAPITAL READINESS REPORT
A concise executive report setting out our overall assessment of the company across all three lenses.
The report highlights the areas supporting the investment case, the most material gaps, and the issues we believe are most likely to attract investor scrutiny.
The question it answers: Where do we stand?
02 | DIAGNOSTICS MODEL
The structured model underlying our assessment.
It captures the detailed findings, evidence, observations and scoring across the Capital Readiness Diagnostic, allowing management to understand exactly what is driving our conclusions.
The question it answers: What is behind the assessment?
03 | PRIORITIZED ACTION PLAN
A practical action plan built directly from the findings.
We identify the issues that matter most before market entry and distinguish between immediate priorities, important improvements and areas requiring no material intervention.
The question it answers: What do we do next?
Three Lenses. One Capital Readiness Assessment.
30 Days Means 30 Days
The Capital Readiness Sprint operates on a hard 30-day timeline. Participating companies must therefore be ready to provide the requested materials immediately following kickoff. Delayed information does not extend the Sprint. That discipline allows us to keep the engagement focused and efficient and allows management to know exactly when the assessment will be complete.
DAY 1
Kickoff and
information request
DAY 2-20
Assessment and
evidence review
DAY 21-27
Findings and prioritization
DAY 30
Final Dliverables
Apply for a Capital Readiness Sprint.
Follow the link and tell us briefly about your company, where you are in your development journey and what you expect from the 2027 capital markets. We review every submission to confirm that the Sprint is appropriate for the company and that the required information can be made available within the 30-day delivery model.
If there is a fit, we will arrange a short introductory conversation to confirm the fixed fee, engagement requirements and available kickoff date.